Overall survival (OS) with afatinib (A) vs chemotherapy (CT) in patients (pts) with NSCLC harboring EGFR mutations (mut): Subgroup analyses by race in LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)

被引：0
|
作者：
Wu, Y. -L. [1 ,2 ]
Sequist, L. V. [3 ,4 ]
Schuler, M. [5 ]
Yamamoto, N. [6 ]
Zhou, C. [7 ]
Hu, C. -P. [8 ]
O'Byrne, K. [9 ,10 ]
Hirsh, V. [11 ]
Mok, T. [12 ]
Zazulina, V. [13 ]
Yang, J. C. -H. [14 ,15 ]
机构：
[1] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[3] Massachusetts Gen Hosp, Dept Thorac Oncol, Boston, MA 02114 USA
[4] Harvard Univ, Sch Med, Boston, MA USA
[5] Univ Hosp Essen, Univ Duisburg Essen, West German Canc Ctr, Essen, Germany
[6] Wakayama Med Univ, Dept Internal Med 3, Wakayama, Japan
[7] Tongji Univ, Shanghai Pulm Hosp, Shanghai 200092, Peoples R China
[8] Cent S Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China
[9] Princess Alexandra Hosp, Translat Res Inst, Brisbane, Qld 4102, Australia
[10] Queensland Univ Technol, Brisbane, Qld 4001, Australia
[11] McGill Univ, Dept Oncol, Montreal, PQ, Canada
[12] Chinese Univ Hong Kong, State Key Lab South China, Hong Kong Canc Inst, Hong Kong, Hong Kong, Peoples R China
[13] Boehringer Ingelheim Ltd UK, Med, Bracknell, Berks, England
[14] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[15] Natl Taiwan Univ, Taipei 10764, Taiwan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
445P
引用
收藏
页码：136 / 136
页数：1
相关论文
共 50 条
  • [31] EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6
    Yi-Long Wu
    Lecia V Sequist
    Cheng-Ping Hu
    Jifeng Feng
    Shun Lu
    Yunchao Huang
    Wei Li
    Mei Hou
    Martin Schuler
    Tony Mok
    Nobuyuki Yamamoto
    Kenneth O'Byrne
    Vera Hirsh
    Neil Gibson
    Dan Massey
    Miyoung Kim
    James Chih-Hsin Yang
    British Journal of Cancer, 2017, 116 : 175 - 185
  • [32] Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)
    Wu, Yi-Long
    Hirsh, Vera
    Sequist, Lecia V.
    Hu, Cheng-Ping
    Feng, Jifeng
    Lu, Shun
    Huang, Yunchao
    Schuler, Martin
    Mok, Tony
    Yamamoto, Nobuyuki
    O'Byrne, Kenneth
    Geater, Sarayut L.
    Zhou, Caicun
    Massey, Dan
    Maerten, Angela
    Lungershausen, Juliane
    Yang, James Chih-Hsin
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2018, 11 (01): : 131 - 141
  • [33] Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations
    Yang, James Chih-Hsin
    Hirsh, Vera
    Schuler, Martin
    Yamamoto, Nobuyuki
    O'Byrne, Kenneth J.
    Mok, Tony S. K.
    Zazulina, Victoria
    Shahidi, Mehdi
    Lungershausen, Juliane
    Massey, Dan
    Palmer, Michael
    Sequist, Lecia V.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (27) : 3342 - +
  • [34] LUX-Lung 3: A Randomized, Open-Label, Phase III Study of Afatinib vs Pemetrexed and Cisplatin as First-Line Treatment for Patients with Advanced Adenocarcinoma of the Lung Harboring EGFR-Activating Mutations (Subgroup Analysis)
    Sequist, L.
    Schuler, M.
    Yamamoto, N.
    O'Byrne, K.
    Hirsh, V.
    Mok, T.
    Massey, D.
    Zazulina, V.
    Shahidi, M.
    Yang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S203 - S203
  • [35] Afatinib Dose Adjustment: Effect on Safety, Efficacy and Patient-Reported Outcomes in the LUX-Lung 3/6 Trials in EGFRm plus NSCLC
    Hirsh, V.
    Tan, E.
    Wu, Y.
    Sequist, L.
    Zhou, C.
    Schuler, M.
    Geater, S.
    Mok, T.
    Hu, C.
    Yamamoto, N.
    Feng, J.
    O'Byrne, K.
    Lu, S.
    Huang, Y.
    Sebastian, M.
    Okamoto, I.
    Dickgreber, N.
    Shah, R.
    Palmer, M.
    Maerten, A.
    Massey, D.
    Samuelsen, C.
    Yang, J. C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2231 - S2231
  • [36] Afatinib (A) vs gefitinib (G) as first-line treatment (tx) for patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC: LUX-Lung 7
    Hirsh, Vera
    Park, Keunchil
    Tan, Eng-Huat
    Zhang, Li
    O'Byrne, Kenneth
    Boyer, Michael
    Yang, James Chih-Hsin
    Mok, Tony
    Fan, Jean
    Massey, Dan
    Paz-Ares, Luis
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [37] Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7)
    Park, K.
    Tan, E-H.
    Zhang, L.
    Hirsh, V.
    O'Byrne, K.
    Boyer, M.
    Yang, J. C-H.
    Mok, T.
    Kim, M.
    Massey, D.
    Zazulina, V.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2015, 26 : 161 - 162
  • [38] Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8).
    Soria, Jean-Charles
    Felip, Enriqueta
    Cobo, Manuel
    Lu, Shun
    Syrigos, Konstantinos N.
    Lee, Ki Hyeong
    Goker, Erdem
    Georgoulias, Vassilis
    Li, Wei
    Isla, Dolores
    Guclu, Salih Zeki
    Morabito, Alessandro
    Min, Young Joo
    Ardizzoni, Andrea
    Gadgeel, Shirish M.
    Wang, Bushi
    Chand, Vikram K.
    Goss, Glenwood D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [39] LUX-lung 3: A randomized, open-label, phase III study of afatinib vs pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations
    Schuler, Martin
    Yang, James Chih-Hsin
    Yamamoto, Nobuyuki
    O'Byrne, Ken
    Hirsh, Vera
    Mok, Tony
    Massey, Dan
    Zazulina, Victoria
    Shahidi, Mehdi
    Sequist, Lecia
    LUNG CANCER, 2012, 77 : S25 - S26
  • [40] First-line afatinib for advanced EGFRm plus NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials
    Schuler, Martin
    Paz-Ares, Luis
    Sequist, Lecia, V
    Hirsh, Vera
    Lee, Ki Hyeong
    Wu, Yi-Long
    Lu, Shun
    Zho, Caicun
    Feng, Jifeng
    Ellis, Stuart H.
    Samuelsen, Carl H.
    Tang, Wenbo
    Marten, Angela
    Ehrnrooth, Eva
    Park, Keunchil
    Yang, James Chih-Hsin
    LUNG CANCER, 2019, 133 : 10 - 19
12345